Rethinking MS Therapeutics: From Disease Pathogenesis Mechanisms to AI-Driven Drug Discovery

J Neuroimmune Pharmacol. 2026 Apr 13;21(1):21. doi: 10.1007/s11481-026-10286-x.

Authors

Maryam Ziaei¹, Mohammadreza Sehhati¹, Mohammadreza Torabi¹, Nafiseh Esmaeil², Fahimeh Ghasemi³

Affiliations

¹ Department of Bioinformatics and Systems Biology, School of Advanced Technologies in Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
² Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. n_esmaeil@med.mui.ac.ir.
³ Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran. f_ghasemi@tums.ac.ir.

PMID: 41973156
DOI: 10.1007/s11481-026-10286-x

No abstract available

Keywords: Artificial intelligence; Diagnosis; Drug design; Multiple sclerosis; Pathogenesis; Therapeutic approaches.

Publication types

Review

Grants and funding